Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Anus Neoplasms, Astrocytoma, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Ependymoma, Esophageal Neoplasms, Glioblastoma, Glioma, Carcinoma, Hepatocellular, Oligodendroglioma, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Neuroectodermal Tumors, Primitive, Esthesioneuroblastoma, Olfactory, Glioma, Subependymal, Gliosarcoma, Breast Neoplasms, Male

NCT00495872 2012-10-18

Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

Phase 1 Completed

204 enrolled

Other solid neoplasm

Solid Tumors

NCT00320073 2012-05-16

Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1 Completed

41 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00137826 2011-12-26

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Phase 2 Completed

37 enrolled

Other solid neoplasmThoracic

Mesothelioma

NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Phase 1 Completed

60 enrolled

GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00754104 2011-01-19

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

Phase 1 Withdrawn

Other solid neoplasm

Solid Tumors

Clinical Trials

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study

A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

Erlotinib in Combination With Pralatrexate in Advanced Malignancies

Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors

Erlotinib and Temsirolimus for Solid Tumors

Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors